Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Lymphoma, Large B-Cell, Diffuse 36Multiple Myeloma 34Burkitt Lymphoma 33Lymphoma 31Leukemia, Myeloid, Acute 30Lymphoma, Non-Hodgkin 29Recurrence 26Breast Neoplasms 26Lymphoma, B-Cell 24Neoplasms 22Lymphoma, Follicular 22Leukemia, Lymphocytic, Chronic, B-Cell 22Myelodysplastic Syndromes 21Hodgkin Disease 18Triple Negative Breast Neoplasms 16Ovarian Neoplasms 16Leukemia 16Hematologic Neoplasms 15Melanoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Neuroblastoma 13Lymphoma, Mantle-Cell 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Pancreatic Neoplasms 11Leukemia, Biphenotypic, Acute 11Lymphoma, B-Cell, Marginal Zone 10Sarcoma 9Neoplasm Metastasis 9Leukemia, Myelomonocytic, Chronic 9

Interventions

Specimen Handling 2remdesivir 1fludarabine 1cabozantinib 1Standard of Care 1Practice Guidelines as Topic 1Platinum Compounds 1Nivolumab 1Methods 1Ipilimumab 1Interviews as Topic 1Educational Status 1Early Intervention, Educational 1Cyclophosphamide 1CTLA-4 Antigen 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Autoimmune Diseases × Cyclophosphamide × 90 days × Clear all
NCT06193889 2026-05-15

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Kyverna Therapeutics

Phase 2/3 Recruiting
66 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡